LON:MDC - Mediclinic International Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 301
  • Forecasted Upside: -0.79 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 303.40
▼ -1.2 (-0.39%)
1 month | 3 months | 12 months
Get New Mediclinic International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 301
▼ -0.79% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Mediclinic International in the last 3 months. The average price target is GBX 301, with a high forecast of GBX 323 and a low forecast of GBX 260. The average price target represents a -0.79% upside from the last price of GBX 303.40.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in Mediclinic International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
7/22/2020BarclaysReiterated RatingEqual weight
i
7/8/2020Jefferies Financial GroupLower Price TargetBuyGBX 482 ➝ GBX 323
i
6/11/2020UBS GroupDowngradeNeutralGBX 400 ➝ GBX 320
i
5/14/2020HSBCUpgradeHoldGBX 270 ➝ GBX 260
i
4/14/2020HSBCLower Price TargetReduceGBX 310 ➝ GBX 270
i
1/21/2020Jefferies Financial GroupBoost Price TargetBuyGBX 457 ➝ GBX 482
i
12/18/2019BarclaysBoost Price TargetEqual weightGBX 360 ➝ GBX 400
i
11/29/2019Jefferies Financial GroupBoost Price TargetBuyGBX 422 ➝ GBX 457
i
11/26/2019UBS GroupDowngradeNeutralGBX 385 ➝ GBX 400
i
11/15/2019Jefferies Financial GroupReiterated RatingBuy
i
10/14/2019UBS GroupReiterated RatingBuyGBX 395 ➝ GBX 385
i
6/20/2019HSBCLower Price TargetHoldGBX 360 ➝ GBX 310
i
6/7/2019UBS GroupReiterated RatingBuyGBX 410 ➝ GBX 395
i
6/4/2019Bank of AmericaUpgradeNeutral
i
4/12/2019BarclaysLower Price TargetEqual weightGBX 460 ➝ GBX 410
i
1/16/2019HSBCLower Price TargetHoldGBX 390 ➝ GBX 360
i
1/7/2019JPMorgan Chase & Co.UpgradeOverweightGBX 480 ➝ GBX 394
i
10/25/2018HSBCUpgradeHoldGBX 540 ➝ GBX 390
i
10/18/2018BarclaysDowngradeEqual weightGBX 660 ➝ GBX 460
i
10/2/2018CitigroupUpgradeBuy
i
9/28/2018BarclaysLower Price TargetOverweightGBX 700 ➝ GBX 660
i
8/9/2018Credit Suisse GroupLower Price TargetNeutralGBX 660 ➝ GBX 550
i
8/7/2018BarclaysLower Price TargetOverweightGBX 751 ➝ GBX 700
i
4/13/2018BarclaysInitiated CoverageOverweightGBX 751
i
2/2/2018BarclaysInitiated CoverageOverweightGBX 751
i
1/30/2018UBS GroupDowngradeNeutralGBX 600 ➝ GBX 650
i
12/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 695
i
11/30/2017Jefferies Financial GroupUpgradeBuyGBX 550 ➝ GBX 616
i
11/21/2017CitigroupReiterated RatingNeutral
i
11/20/2017Credit Suisse GroupLower Price TargetNeutralGBX 783 ➝ GBX 630
i
10/27/2017Jefferies Financial GroupReiterated RatingUnderperformGBX 550
i
10/26/2017Credit Suisse GroupBoost Price TargetNeutralGBX 265 ➝ GBX 305
i
10/26/2017MacquarieReiterated RatingNeutralGBX 660
i
10/24/2017CitigroupReiterated RatingNeutral
i
10/20/2017MacquarieLower Price TargetNeutralGBX 760 ➝ GBX 660
i
10/19/2017JPMorgan Chase & Co.DowngradeNeutralGBX 898 ➝ GBX 733
i
10/18/2017CitigroupLower Price TargetNeutralGBX 790 ➝ GBX 720
i
9/25/2017Jefferies Financial GroupLower Price TargetUnderperformGBX 650 ➝ GBX 550
i
7/21/2017Credit Suisse GroupReiterated RatingNeutral
i
6/29/2017Morgan StanleyDowngradeEqual WeightGBX 825 ➝ GBX 775
i
6/27/2017CitigroupReiterated RatingNeutralGBX 790
i
6/26/2017InvestecDowngradeHoldGBX 775
i
6/1/2017Jefferies Financial GroupBoost Price TargetUnderperformGBX 646 ➝ GBX 650
i
5/5/2017MacquarieBoost Price TargetNeutralGBX 760 ➝ GBX 790
i
4/28/2017InvestecReiterated RatingBuy
i
4/11/2017MacquarieLower Price TargetNeutralGBX 770 ➝ GBX 760
i
4/11/2017CitigroupReiterated RatingNeutral
i
4/4/2017MacquarieDowngradeNeutralGBX 860 ➝ GBX 770
i
2/24/2017UBS GroupDowngradeNeutralGBX 900 ➝ GBX 810
i
2/23/2017Credit Suisse GroupLower Price TargetOutperformGBX 1,045 ➝ GBX 985
i
2/22/2017CitigroupLower Price TargetNeutralGBX 890 ➝ GBX 860
i
2/20/2017Jefferies Financial GroupDowngradeUnderperformGBX 639 ➝ GBX 658
i
2/3/2017MacquarieUpgradeOutperformGBX 830 ➝ GBX 860
i
12/15/2016Jefferies Financial GroupLower Price TargetHoldGBX 741 ➝ GBX 639
i
11/29/2016Jefferies Financial GroupLower Price TargetHoldGBX 812 ➝ GBX 741
i
11/23/2016MacquarieLower Price TargetNeutralGBX 970 ➝ GBX 830
i
11/21/2016UBS GroupLower Price TargetBuyGBX 1,100 ➝ GBX 995
i
11/11/2016Credit Suisse GroupLower Price TargetOutperformGBX 1,120 ➝ GBX 1,045
i
9/28/2016Jefferies Financial GroupLower Price TargetHoldGBX 833 ➝ GBX 812
i
9/22/2016Jefferies Financial GroupLower Price TargetHoldGBX 920 ➝ GBX 833
i
9/12/2016CitigroupDowngradeNeutralGBX 1,090
i
9/6/2016UBS GroupReiterated RatingBuyGBX 1,170
i
8/25/2016Jefferies Financial GroupLower Price TargetBuyGBX 1,070 ➝ GBX 980
i
8/25/2016InvestecReiterated RatingBuyGBX 1,030
i
8/23/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,160
i
7/26/2016Jefferies Financial GroupBoost Price TargetHoldGBX 833 ➝ GBX 920
i
6/28/2016CitigroupUpgradeBuyGBX 990 ➝ GBX 1,150
i
5/27/2016MacquarieReiterated RatingNeutralGBX 900
i
5/24/2016CitigroupReiterated RatingNeutralGBX 920
i
5/11/2016BarclaysInitiated CoverageEqual weightGBX 905
i
5/9/2016InvestecReiterated RatingBuyGBX 984
i
5/6/2016Morgan StanleyInitiated CoverageEqual weightGBX 900
i
4/29/2016MacquarieReiterated RatingNeutralGBX 920
i
(Data available from 4/21/2016 forward)
Mediclinic International logo
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 hospitals, 2 day case clinics, 3 outpatient clinics, and 110 theatres with approximately 1,893 inpatient beds in Switzerland; 52 hospitals, 10 day case clinics, 8 sub-acute hospitals, and 305 theatres in South Africa and Namibia with approximately 8,792 inpatient beds; and 7 hospitals, 2 day case clinics, 18 outpatient clinics, and 38 theatres with approximately 927 inpatient beds in the United Arab Emirates. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
Read More

Today's Range

Now: GBX 303.40
301
309

50 Day Range

MA: GBX 299.32
282.60
319

52 Week Range

Now: GBX 303.40
232.40
343

Volume

140,405 shs

Average Volume

483,908 shs

Market Capitalization

£2.24 billion

P/E Ratio

N/A

Dividend Yield

3.12%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mediclinic International?

The following Wall Street analysts have issued reports on Mediclinic International in the last year: Barclays PLC, HSBC Holdings plc, Jefferies Financial Group Inc., and UBS Group AG.
View the latest analyst ratings for MDC.

What is the current price target for Mediclinic International?

3 Wall Street analysts have set twelve-month price targets for Mediclinic International in the last year. Their average twelve-month price target is GBX 301, suggesting a possible downside of 0.8%. Jefferies Financial Group Inc. has the highest price target set, predicting MDC will reach GBX 323 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of GBX 260 for Mediclinic International in the next year.
View the latest price targets for MDC.

What is the current consensus analyst rating for Mediclinic International?

Mediclinic International currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MDC, but not buy more shares or sell existing shares.
View the latest ratings for MDC.

What other companies compete with Mediclinic International?

How do I contact Mediclinic International's investor relations team?

Mediclinic International's physical mailing address is 6th Floor 65 Gresham Street, LONDON, EC2V 7NQ, United Kingdom. The company's listed phone number is +44-20-79549600. The official website for Mediclinic International is www.mediclinic.com.